Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$27,000.00

Mitochondrial Permeability Transition in Preeclampsia-Induced Damage – Insights into Resolvin-Based Interventions

FY 2024-25

Summary
Preeclampsia (PE) is a dangerous pregnancy complication which can lead to organ failure, seizures, or strokes - accounting for over 70,000 maternal and 500,000 fetal deaths each year. Its causes remain unclear, and current treatments are risky, involving simply managing symptoms or inducing early delivery.The placenta supplies oxygen and nutrients to the fetus during pregnancy. In PE, the placenta is oxygen-deficient, which damages mitochondria - the energy powerhouses of cells. The mitochondria are very sensitive to changes in oxygen concentration, so it is not surprising that mitochondrial damage plays a large role in PE. One critical process which may be involved in this damage is the formation of a pore in the protective outer layer of the mitochondria, called the mPTP, the opening of which leads to cell death. Current research has not yet explored the role of the mPTP in PE. However, a medication which is known to block its opening (called Cyclosporin A) is highly effective in alleviating the signs of PE. Unfortunately, Cyclosporin A also suppresses the immune system, and thus poses risks to the pregnant mother and developing fetus.Our research explores a safer alternative: resolvin, a natural anti-inflammatory derived from omega-3 fatty acids. Resolvin has been shown to block mPTP formation in liver cells without suppressing the immune system. We will be treating placental stem cells with resolvin and exposing them to low-oxygen conditions to mimic PE. We will then assess whether resolvin is able to reduce the characteristic damages seen in PE.By exploring underlying mechanisms and treatment strategies, we seek to fill a critical gap in maternal-fetal medicine, potentially reducing the global burden of PE and improving outcomes for mothers and babies.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530298
Name
Feeney Jenny S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mitochondrial Permeability Transition in Preeclampsia-Induced Damage – Insights into Resolvin-Based Interventions
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cellular Damage; Hypoxia; Inflammation; Mitochondrial Dysfunction; Mitochondrial Morphology; Mitochondrial Permability Transition; Oxidative Stress; Preeclampsia; Resolvin; Trophoblasts
Abstract
Preeclampsia (PE) is a dangerous pregnancy complication which can lead to organ failure, seizures, or strokes - accounting for over 70,000 maternal and 500,000 fetal deaths each year. Its causes remain unclear, and current treatments are risky, involving simply managing symptoms or inducing early delivery.The placenta supplies oxygen and nutrients to the fetus during pregnancy. In PE, the placenta is oxygen-deficient, which damages mitochondria - the energy powerhouses of cells. The mitochondria are very sensitive to changes in oxygen concentration, so it is not surprising that mitochondrial damage plays a large role in PE. One critical process which may be involved in this damage is the formation of a pore in the protective outer layer of the mitochondria, called the mPTP, the opening of which leads to cell death. Current research has not yet explored the role of the mPTP in PE. However, a medication which is known to block its opening (called Cyclosporin A) is highly effective in alleviating the signs of PE. Unfortunately, Cyclosporin A also suppresses the immune system, and thus poses risks to the pregnant mother and developing fetus.Our research explores a safer alternative: resolvin, a natural anti-inflammatory derived from omega-3 fatty acids. Resolvin has been shown to block mPTP formation in liver cells without suppressing the immune system. We will be treating placental stem cells with resolvin and exposing them to low-oxygen conditions to mimic PE. We will then assess whether resolvin is able to reduce the characteristic damages seen in PE.By exploring underlying mechanisms and treatment strategies, we seek to fill a critical gap in maternal-fetal medicine, potentially reducing the global burden of PE and improving outcomes for mothers and babies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Feeney, Jenny S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~